Navigation Links
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Date:9/17/2007

Next-Generation Once-Daily CCR5 Antagonist Designed to Block HIV Infection

of Immune System Cells

KENILWORTH, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has initiated two large Phase III clinical studies with vicriviroc, its investigational CCR5 antagonist, administered once-daily as a single 30 mg tablet in combination with an optimized background therapy that must include a protease inhibitor boosted by ritonavir in adult treatment-experienced HIV patients with R5-type virus only. Vicriviroc is a next-generation extracellular inhibitor of HIV infection designed to block entry of infectious virions into uninfected CD4 cells via antagonism of the CCR5 co-receptor.

The vicriviroc Phase III clinical program builds upon previous studies in HIV treatment-experienced patients, including a Phase II study (ACTG 5211) in which vicriviroc demonstrated potent and sustained viral suppression through 48 weeks of therapy.(1)

The two Phase III studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV- Infected Treatment-Experienced Subjects), will evaluate the virologic benefit of adding vicriviroc 30 mg once daily to an optimized background therapy compared to a control group receiving new optimized background therapy alone. The studies will also evaluate the safety and tolerability of vicriviroc compared to placebo. The optimized background therapy must include at least two drugs that are active, based on susceptibility testing. Patients coinfected with hepatitis C may be included in the studies and there are no exclusions of commonly prescribed drug
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. Malvern initiates European user group meetings for chemical imaging
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... HANOVER, N.J. , April 24, 2015  Novartis Pharmaceuticals ... for the second year in a row on the annual ... results of its 2015 Top 50 Companies for Diversity on ... York, NY . NPC also ranked second on the ... the Top 10 Companies for Employee Resource Groups list. ...
(Date:4/24/2015)... T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"), a ... products and a licensed producer ("LP") to cultivate marijuana ... Canada ) ("MMPR"), is pleased to announce that ... the transaction announced on March 11, 2015 with Medna ... a total of 20,156,790 common shares of T-Bird (45% ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ... Drug Administration (FDA) has accepted its New Drug Application ... interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir ... treatment of adults with chronic genotype 4 (GT4) hepatitis ... the first all-oral, interferon-free therapy being evaluated by the ...
Breaking Medicine Technology:Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 3Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 4T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/25/2015)... 25, 2015 For thirteen years, the Twin ... protection education event in the nation! This year, on May ... Group, US to take DI Day on the road by ... Davidson, CLU, ChFC, RHU, DIA, CLTC, Chief Executive Officer at ... reflects on the change by stating, "The first Twin Cities ...
(Date:4/24/2015)... New York, NY (PRWEB) April 24, 2015 ... upscale sober living residence in Westchester County. Just 35 ... to help transition individuals back into everyday life while ... for Thursday, May 7, 2015, will allow therapists, doctors ... living areas and learn more about the opportunities offered ...
(Date:4/24/2015)... As the nation recognizes the Month of the ... young men and women, the “Alaska – Forget Me ... presents a special training session on Adverse Childhood Experiences ... understanding of the effect of childhood trauma and, in ... and military – who provide services and support to ...
(Date:4/24/2015)... April 24, 2015 Carvers' goal ... have a successful biking day in Breck. , ... five minutes walking distance from Breckenridge, this family-owned ... in both Breckenridge bike rentals ( http://www.breckenridgeskishop.com/en/rent-equipment ) ... offer extensive bike rentals in May 2015. With ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Lipitor ... forward in the federal multidistrict litigation underway in ... to court documents, the parties involved in the ... 16th detailing, among other things, preparation for the ... counsel for both plaintiffs and defendants have conducted ...
Breaking Medicine News(10 mins):Health News:Secura Consultants Takes DI Day On The Road 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Carvers Breckenridge Bike Rentals Offers Demo Mountain, Tandem, Bike Path Cruiser & JR. Bikes in May 2015 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
... Silicone breast implants went through a long period of relative dormancy ... Now, two years after the U.S. Food and Drug Administration approved ... plastic surgeon Richard L. Zeff, MD comments on why he feels ... ...
... Corticon offers special pricing on patent-pending Dialogs, the premier platform ... ... Redwood City, CA (PRWEB) April 2, ... in model-driven Business Rules Management Systems (BRMS), today announced special ...
... Nurse Training, Inc., provider of nurse training seminars on DVD and online ... ... April 2, 2009 -- Medical Nurse Training, Inc., provider of nurse training ... its website., , ,Medical Nurse Training, Inc. provides DVD and online courses ...
... IT, a national provider of medical documentation services and software, announced ... innovative medical documentation company that serves more than 450 healthcare professionals ... ... (PRWEB) April 2, 2009 -- MD IT , a national ...
... pregnancy, such as morning sickness, fatigue and weight gain, but despite this, ... Gurgle, we offer a guide to women in their early stages of ... ... (PRWEB) April 2, 2009 -- Around half of all women will experience ...
... April 2 In the first,quarter of 2009 (December ... figure of EUR237.3m (Q1 2008: EUR239.1m) almost at the ... world economy. In,the core business, however, sales by the ... The operating result (adjusted EBITDA) ...
Cached Medicine News:Health News:New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure 2Health News:New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure 3Health News:New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure 4Health News:Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar 2Health News:Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar 3Health News:Medical Nurse Training, Inc. Announces the Launch of Medicalnursetraining.com 2Health News:MD IT Expands in the Northwest with Acquisition of Seattle's Pro Scribe 2Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 2Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 3Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 4Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 5Health News:Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed 2Health News:Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed 3Health News:Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed 4
Adjustable speed vortex with inter-changeable heads , 110 V...
Adjustable speed vortex with inter-changeable heads, 110 V...
... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
... Vacuum Controller V-800 and water-cooled secondary condenser ... Compact Housing Model V-500 is a ... most vacuum applications. Applications Ideally ... evaporators Laboratory vacuum source for instruments ...
Medicine Products: